Skip to main content
Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
7.54
+0.03 (0.40%)
At close: Apr 28, 2026, 4:00 PM EDT
7.57
+0.03 (0.40%)
Pre-market: Apr 29, 2026, 8:24 AM EDT

Puma Biotechnology Revenue

In the year 2025, Puma Biotechnology had annual revenue of $228.37M, down -0.91%. Puma Biotechnology had revenue of $75.45M in the quarter ending December 31, 2025, with 27.72% growth.

Revenue (ttm)
$228.37M
Revenue Growth
-0.91%
P/S Ratio
1.68
Revenue / Employee
$1,275,816
Employees
179
Market Cap
383.61M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025228.37M-2.10M-0.91%
Dec 31, 2024230.47M-5.17M-2.19%
Dec 31, 2023235.64M7.61M3.34%
Dec 31, 2022228.03M-25.12M-9.92%
Dec 31, 2021253.16M28.05M12.46%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Niagen Bioscience 129.42M
Century Therapeutics 109.16M
Autolus Therapeutics 75.39M
Enanta Pharmaceuticals 66.98M
X4 Pharmaceuticals 35.11M
Lineage Cell Therapeutics 14.56M
Opus Genetics 14.20M
YD Bio 510.36K
Revenue Rankings

PBYI News

More News